High Mobility Group Box 1 (HMGB1) is Associated with Progression and Poor Prognosis in Pancreatic CancerXu Yang Liang1, Qian Qian Li1, Zong Li Zhang2, Chong Qi Jia3, Li Li4, Chun Tao Liu1, Yong Mei Yang5 and Bao Quan Cheng1*
- *Corresponding Author:
- Bao Quan Cheng, MD, PhD
Department of Gastroenterology
Qilu Hospital, Medicine College
Shandong University, Jinan 250012, China
E-mail: [email protected]
Received date: April 30, 2014; Accepted date: June 17, 2014; Published date: June 24, 2014
Citation: Liang XY, Li QQ, Zhang ZL, Jia CQ, Li LI, et al. (2014) High Mobility Group Box 1 (HMGB1) is Associated with Progression and Poor Prognosis in Pancreatic Cancer. J Gastroint Dig Syst 4:190. doi:10.4172/2161-069X.1000190
Copyright: © 2014 Liang XY, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Aim: Increased expression of High Mobility Group Protein Box 1(HMGB1) has been reported with several
different tumor types, but the role of HMGB1 in pancreatic cancer is not fully understood. The aim of this study is to
detect the expression of HMGB1 and evaluate the role of HMGB1 in pancreatic cancer.
Methods: The expression level of HMGB1 in pancreatic cancer cell line PANC-1 was detected by western blot
analysis and reverse transcription PCR. Furthermore, primary tumors tissues of 35 patients with resected pancreatic
cancer(T2-4 N0-2 M0-1) were stained immune histochemically using the polyclonal anti-HMGB1 antibody. The
prognostic relevance of HMGB1 expression was evaluated by univariate Kaplan-Meier among 35 patients.
Results: HMGB1 is over expressed in pancreatic cancer.HMGB1 overexpression was significantly associated
with clinical stage (p<0.05). Univariate Cox regression showed that the survival time was significantly different
between groups with high and low expression of HMGB1, indicating that high level of HMGB1correlated with a
shorter survival time (P<0.05; HR, 2.53; 95%CI, 1.14-5.64).
Conclusions: HMGB1 might promote pancreatic cancer progression and HMGB1 expression was an
independent prognostic indicator for patients’ survival